Concepedia

Jurij Stekar

JS

Statistics

Publications

13

Citations

1.1K

H-Index

13

Active since

1968

Affiliations

Astellas Pharma (Japan)(Current)

Hochschule Bielefeld

Jurij Stekar is an author at Astellas Pharma (Japan) specializing in pharmacology, chemotherapy, and medicine.

Publications per year

1968–2015

13

Publications

13

Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

N Brock, Jurij Stekar, J. Pohl et al. · PubMed · 1979 · 187 citations

, , +11

D-21266, a new heterocyclic alkylphospholipid with antitumour activity

P. Hilgard, T. Klenner, Jurij Stekar et al. · European Journal of Cancer · 1997 · 134 citations

, , +5

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)

N Brock, Jörg Pohl, Jurij Stekar et al. · European Journal of Cancer and Clinical Oncology · 1982 · 128 citations

, , +5

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention

N Brock, Jörg Pohl, Jurij Stekar · European Journal of Cancer and Clinical Oncology · 1981 · 112 citations

, , +8

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—I

N Brock, Jörg Pohl, Jurij Stekar · European Journal of Cancer (1965) · 1981 · 111 citations

, , +6

1–5 of 13